| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6677358 | GEMINI LABS LLC | NIDDM regimen |
Jun, 2018
(5 years ago) | |
Prandin is owned by Gemini Labs Llc.
Prandin contains Repaglinide.
Prandin has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Prandin are:
- US6677358
Prandin was authorised for market use on 22 December, 1997.
Prandin is available in tablet;oral dosage forms.
Prandin can be used as patented method of using repaglinide in combination with metformin as indicated for improving glycemic control in adults with type 2 diabetes mellitus.
The generics of Prandin are possible to be released after 12 June, 2018.
Drugs and Companies using REPAGLINIDE ingredient
Market Authorisation Date: 22 December, 1997
Treatment: Patented method of using repaglinide in combination with metformin as indicated for improving glycemic control in adults with type 2 diabetes mellitus
Dosage: TABLET;ORAL
PRANDIN family patents
